Elevance Health (ELV) to Release Earnings on Tuesday

Elevance Health (NYSE:ELV) is projected to issue its quarterly earnings data before the market opens on Tuesday, April 22nd. Analysts expect Elevance Health to post earnings of $10.60 per share and revenue of $46.26 billion for the quarter. Elevance Health has set its FY 2025 guidance at 34.150-34.850 EPS.Individual that are interested in participating in the company’s earnings conference call can do so using this link.

Elevance Health (NYSE:ELV) last announced its quarterly earnings data on Thursday, January 23rd. The company reported $3.84 EPS for the quarter, topping analysts’ consensus estimates of $3.80 by $0.04. Elevance Health had a return on equity of 18.28% and a net margin of 3.38%. On average, analysts expect Elevance Health to post $34 EPS for the current fiscal year and $39 EPS for the next fiscal year.

Elevance Health Stock Up 0.3 %

NYSE ELV opened at $441.02 on Tuesday. The business’s fifty day simple moving average is $413.71 and its 200-day simple moving average is $411.99. The company has a quick ratio of 1.50, a current ratio of 1.45 and a debt-to-equity ratio of 0.71. The firm has a market cap of $99.84 billion, a PE ratio of 17.22, a P/E/G ratio of 1.18 and a beta of 0.77. Elevance Health has a 52 week low of $362.21 and a 52 week high of $567.26.

Elevance Health Increases Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Tuesday, March 25th. Investors of record on Monday, March 10th were given a $1.71 dividend. This represents a $6.84 annualized dividend and a yield of 1.55%. This is a positive change from Elevance Health’s previous quarterly dividend of $1.63. The ex-dividend date of this dividend was Monday, March 10th. Elevance Health’s dividend payout ratio is presently 26.71%.

Wall Street Analyst Weigh In

A number of research firms recently weighed in on ELV. Stephens cut shares of Elevance Health from an “overweight” rating to an “equal weight” rating and lowered their price objective for the stock from $520.00 to $440.00 in a research report on Wednesday, January 22nd. StockNews.com raised Elevance Health from a “hold” rating to a “buy” rating in a research note on Thursday, March 20th. Guggenheim started coverage on Elevance Health in a research note on Wednesday, April 9th. They set a “buy” rating and a $518.00 target price on the stock. Sanford C. Bernstein reaffirmed an “outperform” rating on shares of Elevance Health in a research report on Friday, March 28th. Finally, Mizuho increased their price target on shares of Elevance Health from $455.00 to $505.00 and gave the stock an “outperform” rating in a research report on Wednesday, April 9th. Two analysts have rated the stock with a hold rating, sixteen have issued a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $521.47.

Insider Buying and Selling

In other news, EVP Charles Morgan Kendrick, Jr. sold 3,504 shares of Elevance Health stock in a transaction dated Wednesday, March 5th. The stock was sold at an average price of $396.30, for a total transaction of $1,388,635.20. Following the sale, the executive vice president now owns 10,116 shares in the company, valued at approximately $4,008,970.80. The trade was a 25.73 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CAO Ronald W. Penczek sold 443 shares of the company’s stock in a transaction dated Monday, March 10th. The shares were sold at an average price of $415.13, for a total value of $183,902.59. Following the completion of the sale, the chief accounting officer now directly owns 1,847 shares of the company’s stock, valued at approximately $766,745.11. This trade represents a 19.34 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 0.35% of the stock is owned by company insiders.

About Elevance Health

Elevance Health, Inc, together with its subsidiaries, operates as a health benefits company in the United States. The company operates through four segments: Health Benefits, CarelonRx, Carelon Services, and Corporate & Other. It offers a variety of health plans and services to program members; health products; an array of fee-based administrative managed care services; and specialty and other insurance products and services, such as stop loss, dental, vision, life, disability, and supplemental health insurance benefits.